Document:

Supply Agreement

 EXHIBIT 10.2 
 EXECUTION VERSION 
 [NOTE: CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN MARKED TO INDICATE THAT CONFIDENTIAL
INFORMATION HAS BEEN OMITTED. CONFIDENTIALITY HAS BEEN REQUESTED FOR THIS CONFIDENTIAL INFORMATION. THE CONFIDENTIAL PORTIONS HAVE BEEN PROVIDED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION] 
  

 SUPPLY AGREEMENT FOR ACTIVE
PHARMACEUTICAL INGREDIENT 
 by and between 
 INSPIRE PHARMACEUTICALS, INC. 
 and 
 INSITE VISION INCORPORATED 
 Dated as of February 15, 2007

  

 TABLE OF CONTENTS 
  

					
	 	 	 	  	Page
	ARTICLE 1	 	DEFINITIONS	  	1
			
	ARTICLE 2	 	MANUFACTURE AND SUPPLY OF API	  	6
			
	ARTICLE 3	 	ORDERS AND FORECASTING; EIGHTEEN MONTH SUPPLY; DELIVERY	  	6
			
	ARTICLE 4	 	PASSING OF TITLE AND RISK OF LOSS IN API	  	9
			
	ARTICLE 5	 	PRICE OF API	  	9
			
	ARTICLE 6	 	INVOICE AND PAYMENT	  	10
			
	ARTICLE 7	 	CAPACITY	  	11
			
	ARTICLE 8	 	COMPLAINTS AND PRODUCT RECALL	  	11
			
	ARTICLE 9	 	REJECTION AND REPLACEMENT OF DEFECTIVE API	  	12
			
	ARTICLE 10	 	QUALITY ASSURANCE; REGULATORY COMPLIANCE; AUDITS AND INSPECTION; PRODUCT LICENSE; MANUFACTURING LICENSE; DOCUMENTATION AND REPORTS	  	14
			
	ARTICLE 11	 	CONFIDENTIALITY	  	15
			
	ARTICLE 12	 	FORCE MAJEURE EVENT	  	17
			
	ARTICLE 13	 	REPRESENTATIONS AND WARRANTIES	  	17
			
	ARTICLE 14	 	LIABILITY AND INDEMNIFICATION	  	19
			
	ARTICLE 15	 	INSURANCE	  	21
			
	ARTICLE 16	 	TERM; TERMINATION; REMEDIES	  	22
			
	ARTICLE 17	 	MISCELLANEOUS	  	25

					
			
	SCHEDULES	 		  	
			
	SCHEDULE 1	 	SPECIFICATIONS	  	
			
	SCHEDULE 2	 	PRICE	  	

 SUPPLY AGREEMENT 
 This SUPPLY AGREEMENT (this “Agreement”) is made and entered into as of the 15th day of February, 2007 (the “Effective Date”) by and between INSPIRE PHARMACEUTICALS, INC., a Delaware
corporation having its principal office at 4222 Emperor Boulevard, Suite 200, Durham, North Carolina 27703 (the “Purchaser”), and InSite Vision Incorporated, a Delaware corporation having its principal office at 965 Atlantic Avenue,
Alameda, California 94501 (the “Supplier”). The Purchaser and the Supplier are sometimes referred to herein individually as a “Party” and collectively as “Parties.” 
 RECITALS 
 WHEREAS, [***] is engaged
in the business of manufacturing and supplying the active pharmaceutical ingredient azithromycin [***]; 
 WHEREAS, the Supplier purchases
azithromycin [***] from [***] pursuant to that certain Commercial Supply/Purchase Agreement dated April 1, 2005 by and between the Supplier and [***] (the “[***] Agreement”); and 
 WHEREAS, the Purchaser desires to purchase azithromycin [***] manufactured by [***] from the Supplier. 
 NOW, THEREFORE, in consideration of the foregoing recitals, mutual covenants, agreements, representations and warranties contained herein, the Parties
hereby agree as follows: 
 ARTICLE 1 
 DEFINITIONS 
 In this Agreement: 
 1.1 “Affiliate” means a corporation or non-corporate business entity that, directly or indirectly, controls, is controlled by, or is under common control with the Person specified. An entity will be regarded as in control
of another entity if: (i) it owns, directly or indirectly, at least 50% of the voting securities or capital stock of such entity, or has other comparable ownership interest with respect to any entity other than a corporation; or (ii) it
possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or non-corporate business entity, as applicable, whether through the ownership or control of voting securities, by
contract or otherwise. 
  
 *Indicates that certain information contained herein
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 1 

 1.2 “Agreement” means this Supply Agreement together with all of its schedules (the
“Schedules”). 
 1.3 “API” means the active pharmaceutical ingredient azithromycin [***] as described in the relevant
Specifications for use by the Purchaser and/or Purchaser’s Nominated Contract Manufacturer in the manufacture of Product pursuant to the License Agreement. 
 1.4 “Applicable Laws” means all Legal Requirements applicable to the Manufacture of API, including not only in the country of Manufacture but also (i) where API is to be supplied to another country, the Legal
Requirements in such country applicable to the Manufacture and sale of Product in such country and (ii) the Legal Requirement of the United States, including the Regulatory Acts, applicable to the Manufacture and sale of Product in the United
States. 
 1.5 “Business Day” means any day, except Saturday and Sunday, on which commercial banking institutions in New York are open for
business. Any reference in this Agreement to “day” whether or not capitalized shall refer to a calendar day, not a Business Day. 
 1.6
“Certificate of Analysis” means a certificate provided by a representative of [***] authenticating the pharmaceutical analysis of each batch of API supplied under this Agreement. 
 1.7 “Commercially Reasonable Efforts” means, with respect to the efforts of a particular Party to complete specific tasks or obligations under this
Agreement, the efforts and resources that would be used, consistent with prevailing pharmaceutical industry standards, by a company of similar size and scope to such Party taking into account efficacy, safety and other relevant factors. Commercially
Reasonable Efforts shall be determined on a country-by-country basis. With respect to the efforts of the Supplier to compel [***] to undertake any action as required under this Agreement, the Supplier’s rights and obligations under the [***]
Agreement shall be considered in the determination of what efforts constitute Commercially Reasonable Efforts. 
 1.8 “Confidential
Information” of a Party means all secret, confidential or proprietary information or data, whether provided in written, oral, graphic, video, computer or other form, provided by such Party (the “Disclosing Party”) to the
other Party (the “Receiving Party”) pursuant to this Agreement (including information generated by or on behalf of such Party pursuant to this Agreement and disclosed to the other Party), which may include without limitation
information relating to the Disclosing Party’s existing or proposed research, development efforts, patent applications, business or products and any other materials that have not been made available by the Disclosing Party to the general
public. The terms of this Agreement shall also be deemed Confidential Information of each Party, except to the extent 
  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  

 2 

 
disclosed pursuant to Section 11.3 herein. Notwithstanding the foregoing sentences, the term “Confidential Information” shall not include any
information or materials that the Receiving Party can demonstrate: 
 (a) were already known to the Receiving Party (other than under an
obligation of confidentiality), at the time of disclosure by the Disclosing Party to the extent such Receiving Party has documentary evidence to that effect; 
 (b) were generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; 
 (c) became generally available to the public or otherwise part of the public domain after its disclosure or development, as the case may be, and other than through any act or omission of the Receiving Party in breach
of its confidentiality obligations under this Agreement; 
 (d) were subsequently lawfully disclosed to the Receiving Party by a Third Party
who had no obligation to the Disclosing Party not to disclose such information to others; 
 (e) were independently discovered or developed by
or on behalf of the Receiving Party without the use of the Confidential Information belonging to the other Party and the Receiving Party has documentary evidence to that effect; or 
 (f) is approved for release by the Disclosing Party in writing. 
 1.9 “Consent” means any consent, authorization, permit, certificate, license or approval of, exemption by, or filing with, any Regulator or other Person. 
 1.10 “Current Good Manufacturing Practices” or “cGMPs” shall mean the then-current version of ICH-Q7A Good Manufacturing Practice Guidance For Active Pharmaceutical Ingredients and
the then-current principles detailed in the U.S. Current Good Manufacturing Practices, 21 CFR Parts 210 and 211. 
 1.11 “Delivery” means in
each case the delivery of API in accordance with the requirements of Section 4.1. 
 1.12 “Disclosing Party” has the meaning set forth
in Section 1.8. 
  
 *Indicates that certain information contained herein has
been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 3 

 1.13 “DMF” means in relation to API the Drug Master File containing all the information on the
production and control of API. 
 1.14 “Effective Date” has the meaning set forth in
the first (1st) paragraph hereof. 
 1.15 “Eighteen Month Supply” means the quantity of API forecasted in the applicable Forecast Schedule. 
 1.16 “FDA” means the United States Food and Drug Administration, or any successor agency thereof. 
 1.17 “Firm
Order” or “Firm Orders” has the meaning set forth in Section 3.3. 
 1.18 “Force Majeure Event” has the
meaning set forth in Section 12.1. 
 1.19 “Forecast Schedule” has the meaning set forth in Section 3.2. 
 1.20 “Good Condition” means that API supplied is the right product, made in accordance with the registered process, has in no way deteriorated or broken
down, is not damaged or contaminated upon Delivery, is in the right container, is correctly labelled and properly sealed in its container, accords with the relevant Specifications and is capable of any agreed standard of performance. 
 1.21 “Indemnitee” has the meaning set forth in Section 14.3(a). 
 1.22 “Indemnitor” has the meaning set forth in Section 14.3(a). 
 1.23 “Independent
Laboratory” means such laboratory as shall be mutually agreed in writing between the Parties for the purpose of Article 9. 
 1.24 “Initial
Term” has the meaning set forth in Section 16.1. 
 1.25 “Knowledge” means, with respect to a particular fact or matter, the
applicable Party or its Affiliate is actually aware of that fact or matter as of the Effective Date following a reasonably comprehensive internal investigation among such Party’s or Affiliate’s officers and employees who could reasonably
be expected to be aware of such fact or matter. 
  
 *Indicates that certain
information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 4 

 1.26 “Legal Requirements” shall mean any and all applicable local, municipal, provincial, federal and
international laws, statutes, ordinances, rules, regulations or operating procedures now or hereafter enacted or promulgated by any Regulator, including the Regulatory Acts. 
 1.27 “License Agreement” shall mean that certain License Agreement by and between the Purchaser and the Supplier dated as of February 15, 2007. 
 1.28 “Loss” or “Losses” has the meaning set forth in Section 14.1. 
 1.29 “Manufacture” or “Manufacturing” means the planning, purchasing, manufacture, processing, compounding, storage, filling, packaging, waste disposal, labelling, leafleting,
testing, quality assurance, sample retention, stability testing, release, dispatch and supply of API. 
 1.30 “Manufacturing License” means
all licenses necessary for or required in connection with the Manufacture of API at the Manufacturing Site. 
 1.31 “Manufacturing Site”
means the manufacturing facility of [***] at [***]. 
 1.32 “Material Safety Data Sheet” means the material safety data sheet provided by a
representative of [***] with respect to each batch of API supplied under this Agreement. 
 1.33 “Other Purchaser Default” has the meaning
set forth in Section 16.6. 
 1.34 “Other Supplier Default” has the meaning set forth in Section 16.3. 
 1.35 “Party” or “Parties” has the meaning set forth in the first (1st) paragraph hereof. 
 1.36
“Person” or “person” means any individual, firm, corporation, partnership, limited liability company, trust, unincorporated organization or other entity or a government agency or political subdivision thereto, and
shall include any successor (by merger or otherwise) of such Person. 
 1.37 “Price” means the price of API calculated pursuant to Article
5. 
 1.38 “Product” means the finished pharmaceutical products Manufactured by Purchaser pursuant to the License Agreement that contain API
as an active ingredient. 
 1.39 “Purchaser” has the meaning set forth in the first
(1st) paragraph hereof. 
  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 
  

 5 

 1.40 “Purchaser Indemnitee” has the meaning set forth in Section 14.1. 
 1.41 “Purchaser Material Default” has the meaning set forth in Section 16.5. 
 1.42 “Purchaser’s Nominated Contract Manufacturer” means Cardinal Health PTS, LLC and such other Third Party manufacturer reasonably acceptable to Supplier as may be confirmed by the Purchaser to
the Supplier in writing from time to time as being appointed by the Purchaser to manufacture Product on behalf of the Purchaser and to whom supplies of API shall be Delivered for this purpose pursuant to this Agreement. 
 1.43 “Receiving Party” has the meaning set forth in Section 1.8. 
 1.44 “Regulator” means any relevant nation or government, any state, province, or other political subdivision thereof or any entity with legal authority to exercise executive, legislative, judicial,
regulatory or administrative functions or pertaining to government which regulates any aspect of the Manufacture of API or active pharmaceutical ingredient in general and/or the sale or marketing of any Product, including any division of the FDA (as
applicable) and any other applicable counterpart agency that administers the Regulatory Acts of any jurisdiction. 
 1.45 “Regulatory Acts”
means all Applicable Laws and regulations that govern the approval, manufacture, sale or licensing of pharmaceutical products, or ingredients for inclusion therein, including, without limitation, the United States Federal Food, Drug and Cosmetic
Act, as amended and the rules and regulations promulgated thereunder. 
 1.46 “Renewal Term” has the meaning set forth in Section 16.1.

 1.47 “[***]” has the meaning set forth in the first (1st) recital hereof. 
 1.48 “[***] Agreement” has the meaning set forth in the second (2nd) recital hereof. 
 1.49 “[***] Confidential Information” means Confidential Information (as defined in the [***]
Agreement) of [***] received by the Supplier pursuant to the [***] Agreement. 
 1.50 “Schedules” has the meaning set forth in
Section 1.2. 
 1.51 “SEC” has the meaning set forth in Section 11.2. 
 1.52 “Seed Stock” has the meaning set forth in Section 3.1. 
  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 
  

 6 

 1.53 “Specifications” means the specifications for API as identified in Schedule 1. 

1.54 “Supplier” has the meaning set forth in the first (1st) paragraph hereof. 
 1.55 “Supplier
Indemnitee” has the meaning set forth in Section 14.2. 
 1.56 “Supplier Material Default” has the meaning set forth in
Section 16.2. 
 1.57 “Term” has the meaning set forth in Section 16.1. 
 1.58 “Third Party(ies)” means any Person other than the Supplier, the Purchaser and their respective Affiliates. 
 1.59 “Third Party Claim” means any Third Party claim, demand, suit, action or proceeding. 
 ARTICLE 2 
 MANUFACTURE AND SUPPLY OF API 
 2.1 Manufacture and Supply. In accordance with the terms of this Agreement, the Supplier shall sell to the Purchaser those requirements for API Manufactured by
[***] as forecasted and ordered from time to time by the Purchaser in accordance with Article 3, and shall supply such quantities of API to the Purchaser and/or Purchaser’s Nominated Contract Manufacturer (as applicable) for use in the
Manufacture of Product. 
 2.2 Compliance with Specifications; Quality Standards. All API supplied hereunder shall comply with the warranty set forth
in Section 13.2(c). 
 2.3 [***] Agreement. The Supplier shall comply with all material terms and conditions set forth in the [***] Agreement.

 ARTICLE 3 
 ORDERS AND
FORECASTING; EIGHTEEN MONTH SUPPLY; DELIVERY 
 3.1 Seed Stock. The Supplier shall Deliver to Purchaser and/or Purchaser’s Nominated Contract
Manufacturer [***] (the “Seed Stock”). The Seed Stock shall be Delivered as follows: (a) [***] in the aggregate of API on the date hereof; and (b) sufficient quantities of API so that the Seed Stock equals [***] in the
aggregate of API on [***]. Title and risk of loss for the Seed Stock shall transfer to Purchaser in accordance with Section 4.2. Purchaser shall pay for the Seed Stock as follows: (y) notwithstanding Section 6.1, [***]upon shipment of
the Seed Stock in accordance with Section 6.1. 
  
 *Indicates that certain
information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 7 

 3.2 Quarterly Forecast. The Purchaser and/or
Purchaser’s Nominated Contract Manufacturer (as applicable) shall provide the Supplier with a rolling forecast schedule of demand showing their estimated requirements for API for the following [***] months (“Forecast
Schedule”). The Forecast Schedule shall be updated [***] and shall contain, in addition to quantity of API required, the requested delivery date. The first such Forecast Schedule shall be provided to the Supplier on the date hereof and
thereafter by the first (1st) day of each [***]. All forecasts and orders under this Agreement shall be in
multiples of the minimum order quantity of [***]. 
 3.3 Eighteen Month Supply. The Supplier shall build up at the Purchaser’s or
Purchaser’s Nominated Contract Manufacture’s (as applicable) location the Eighteen Month Supply of API in accordance with the following schedule: (a) [***] in the aggregate of API on the date hereof; (b) [***] in the aggregate of
API on June 30, 2007; (c) [***] in the aggregate of API on December 31, 2007; and (d) the Eighteen Month Supply shall be fully Delivered on June 30, 2008. The Seed Stock shall be part of the Eighteen Month Supply and shall
be included in determining the quantity of the Eighteen Month Supply at all times. At all times after June 30, 2008 during the term of this Agreement, the Supplier shall ensure that API is Delivered to Purchaser or Purchaser’s Nominated
Contract Manufacturer in amounts sufficient to maintain, in the aggregate, the Eighteen Month Supply. Notwithstanding the preceding sentence, Purchaser acknowledges and agrees that the Supplier shall not be in breach of such obligation to maintain
the Eighteen Month Supply if: (y) the quantity of API in inventory at the Purchaser’s or Purchaser’s Nominated Contract Manufacturer’s (as applicable) location, in the aggregate, falls below the Eighteen Month Supply while
awaiting Delivery of API from [***] on orders already placed by the Supplier for the benefit of the Purchaser; or (z) the amount of API required for the Eighteen Month Supply increases as a result of the Purchaser’s Forecast Schedule and
the Supplier is using its Commercially Reasonable Efforts to expedite Delivery of such increased amount in accordance with the Supplier’s then-current ordering processes with [***] so long as (i) Delivery occurs no later than seven
(7) months from the date of such Forecast Schedule and (ii) the Supplier satisfies such increase from the Supplier’s own inventory of API by allocating its existing stock among the Purchaser and such other Third Parties to whom the
Supplier supplies API on a pro rata basis. If the Supplier allocates API to the Purchaser from the Supplier’s own inventory, the Parties will discuss in good faith how such allocation will be documented and applied toward the Supplier’s
obligations under this Section 3.3. The Purchaser shall be responsible for all storage, insurance and other costs required to maintain the Eighteen Month Supply; provided, however, the Supplier shall reimburse the Purchaser for one-third
(1/3) of all such reasonable and documented costs within thirty (30) days of invoice thereof by the Purchaser. 
  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  

 8 

 3.4 Firm Orders. Upon submittal of each Forecast Schedule, the quantities of API required for the Supplier to meet
its obligations under Section 3.3 above will be regarded by the Parties as a binding irrevocable commitment (each a “Firm Order”) by the Purchaser to buy from the Supplier, and by the Supplier to supply (or cause to be
supplied) to the Purchaser and/or Purchaser’s Nominated Contract Manufacturer (as appropriate). 
 3.5 Confirmation of Firm Orders. The Supplier
shall respond to each Firm Order received from the Purchaser within thirty (30) days of receipt. The response shall include confirmation of the delivery dates and quantity as set out in the Firm Order. In the event that discussion is required
regarding the timing of production and Delivery, then the relevant planning personnel from both Parties will agree and confirm any amendments to the Firm Order within ten (10) days of receipt by the Supplier of the original Firm Order.

 3.6 Changes to Firm Orders. The Supplier shall satisfy the Purchaser’s requirements pertaining to each Firm Order and, subject to the
Supplier’s rights under the [***] Agreement, shall use Commercially Reasonable Efforts to satisfy any changes in quantity, Delivery phasing or dates requested by the Purchaser in respect of such a Firm Order. In the event that the Supplier
becomes aware that any Firm Order will not be satisfied, then the Supplier shall inform the Purchaser as soon as reasonably practicable and in any event within ten (10) Business Days. This shall be without prejudice to the Purchaser’s
rights under this Agreement in respect of failure to meet Firm Orders. 
 3.7 Shipment. Each lot of API shall be shipped in reinforced cardboard boxes
bagged in foil laminate pouches that meet U.S. Department of Transportation requirements per 49 CFR 171 and 178, as applicable, and each container will be clearly labelled with the weight, name, lot number, and expiration date. The Purchaser or
Purchaser’s Nominated Contract Manufacturer (as appropriate) shall be provided with each Delivery the commercial invoice bearing the applicable order number relating to such Delivery and any other agreed Delivery documentation. At the
Purchaser’s request, the Supplier shall provide the Purchaser with reasonable access to any applicable supporting data in the Supplier’s possession, available to the Supplier or that the Supplier is able to obtain using Commercially
Reasonable Efforts. 
 3.8 Delivery. Delivery shall take place within the period from two days prior to two days after the delivery date contained in
the Firm Order. If API is incorrectly delivered according to the Firm Order, the Supplier shall be held responsible for any reasonable and documented additional expense incurred in Delivering it to the correct point specified in the Firm Order.

  
 *Indicates that certain information contained herein has been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 9 

 3.9 Incomplete Delivery. The Purchaser or, if relevant, Purchaser’s Nominated Contract Manufacturer shall
notify the Supplier as soon as reasonably practicable if there is an incomplete delivery according to the terms of this Agreement. If the Supplier is notified by telephone or in person, then such notification shall be confirmed in writing. The
Supplier shall then be obligated to rectify the incomplete delivery within sixty (60) days, running from the first date the Supplier receives such notification, provided this shall be without prejudice to any other rights or obligations under
this Agreement. In addition, the Supplier shall rectify the incomplete delivery from the Supplier’s own inventory of API by allocating its existing stock among the Purchaser and such other Third Parties to whom the Supplier supplies API on a
pro rata basis. If the Supplier allocates API to the Purchaser from the Supplier’s own inventory, the Parties will discuss in good faith how such allocation will be documented and applied toward the Supplier’s obligations under
Section 3.3. 
 3.10 Certificate of Analysis; Material Safety Data Sheet. At the time of Delivery to the Purchaser or Purchaser’s Nominated
Contract Manufacturer, the Purchaser shall be provided one (1) completed copy of the Certificate of Analysis and Material Safety Data Sheet relating to each batch of API Delivered. 
 3.11 Discontinuation. The Supplier shall notify the Purchaser in writing no less than twelve (12) months prior to such time as [***] may discontinue the manufacture of the API. The Purchaser shall have the
right to purchase up to 150 additional kilograms of API on or prior to the effective date of such discontinuance. 
 3.12 Failure to Supply. If for
any reason (including without limitation as a result of negligence, fault or omission of the Supplier or a Force Majeure Event) API is not able to be supplied to the Purchaser or the Eighteen Month Supply is not maintained at the amount required
under Section 3.3 (or the Supplier anticipates that API will not be supplied to the Purchaser in accordance with any order placed in accordance with Article 3 or the Eighteen Month Supply will not be maintained at the amount required under
Section 3.3), the Supplier shall, as soon as it becomes aware of the fact, give written notice to the Purchaser of the reasons for the shortfall. If the Supplier is in breach of its obligations under Section 3.3 and cannot for any reason
whatsoever meet any such shortfall from allocation of Supplier’s existing stock, then the Purchaser may, without prejudice to its other rights and remedies pursuant to the Agreement or available at law, select and qualify a new supplier to
manufacture and supply API to the Purchaser, and the reasonable and documented costs of such qualification shall be borne by the 
  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  

 10 

 
Supplier. In the event the Purchaser selects and qualifies a new supplier pursuant to the preceding sentence, at the Supplier’s written request:
(a) the Purchaser and the Supplier shall use Commercially Reasonable Efforts to agree to a mutually acceptable arrangement where the Purchaser supplies the Supplier some portion of the API received by the Purchaser from such new supplier; or
(b) the Purchaser will use Commercially Reasonable Efforts to assist the Supplier to obtain the right to order API directly from such new supplier. 
 3.13 Secondary Supplier. At any time while this Agreement is in effect, the Purchaser may select and qualify a secondary supplier (at the Purchaser’s sole expense) to manufacture and supply API to the Purchaser. 
 3.14 Regular Meetings. In order to promote efficient and effective supply chain planning, the appropriate personnel from the Parties’ respective
manufacturing organizations will meet on a regular basis (and in any event no less than once each year) during the term of this Agreement to discuss, consider and implement such measures as they consider appropriate to manage the demand and supply
aspects of this Agreement and review performance. 
 ARTICLE 4 
 PASSING OF TITLE AND RISK OF LOSS IN API 
 4.1 Shipment; Transport. API shall be
Delivered to the Purchaser or Purchaser’s Nominated Contract Manufacturer (as specified in the Firm Order) FCA (Incoterms 2000 edition, published by the International Chamber of Commerce, ICC Publication 560) the location specified in the Firm
Order, except with regard to title and risk of loss, which is described below in Section 4.2. 
 4.2 Title; Risk of Loss. Title and risk of loss
in API shall remain with the Supplier until receipt by the Purchaser or Purchaser’s Nominated Contract Manufacturer (as the case may be), at which point title and risk of loss shall pass to the Purchaser or Purchaser’s Nominated Contract
Manufacturer (as the case may be). 
 4.3 No Acceptance. Neither payment by nor passing of title or risk in API to the Purchaser or Purchaser’s
Nominated Contract Manufacturer (as the case may be) shall be deemed to constitute acceptance of API. 
 ARTICLE 5 
 PRICE OF API 
 5.1 Price. The Price payable by
the Purchaser for API shall be calculated in accordance with Schedule 2. The Price and any other amounts payable pursuant to this Agreement shall be as stated and exclude the cost of Delivery, insurance and packing costs and applicable taxes
and duties which shall be paid by the Purchaser. 
  
 *Indicates that certain
information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 11 

 5.2 Annual Review. The Supplier will keep accurate books and accounts of record in connection with its purchase of
API from [***] in sufficient detail to permit accurate determination of all figures necessary for verification of payment obligations set forth in this Article 5. The Parties shall meet annually during the term of this Agreement (unless otherwise
mutually agreed in writing) to review the Price payable by the Purchaser. Prior to such meeting, the Supplier shall (subject to the Supplier’s confidentiality obligations to [***] (which the Supplier shall use Commercially Reasonable Efforts to
compel [***] to waive)) provide the Purchaser with the details of the pricing at which the Supplier purchases API from [***]. 
 ARTICLE 6

 INVOICE AND PAYMENT 
 6.1
Invoices. Upon shipment of API, the Supplier shall invoice the Purchaser for the relevant quantity of API contained in such shipment. Each invoice issued by the Supplier hereunder shall specify: 
 (a) The Price in respect of API shipped; 
 (b)
The quantity of API shipped and the corresponding Firm Order; and 
 (c) Any other amounts reimbursable to the Supplier pursuant to this
Agreement. 
 6.2 Payment. Payment to the account identified by the Supplier in writing and shall be made in either Euros or United States Dollars in
the Purchaser’s discretion. If a conversion in currency is required, the amount of payment shall be determined by converting the price in Schedule 2 to United States Dollars according to the exchange rate listed in the Wall Street
Journal on the date of payment. Payments shall be made within thirty (30) days from the date of Supplier’s invoice to the account identified by the Supplier in writing. 
 6.3 Taxes. 
 (a) The Purchaser shall pay and otherwise be responsible for all applicable sales, goods
and services and transfer taxes in connection with any payment made to the Supplier pursuant to this Agreement. 
  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  

 12 

 (b) Any income or other tax that one Party hereunder is required to withhold and pay on behalf of the
other Party hereunder with respect to amounts payable under this Agreement shall be deducted from and offset against said amounts prior to payment to the other Party; provided, however, that in regard to any tax so deducted, the Party making the
withholding shall give or cause to be given to the other Party such assistance as may reasonably be necessary to enable that other Party to claim exemption therefrom or credit therefor, and in each case shall furnish the Party on whose behalf
amounts were withheld proper evidence of the taxes paid on its behalf. Each Party shall comply with reasonable requests of the other Party to take any proper actions that may minimize any withholding obligation. 
 ARTICLE 7 
 CAPACITY 

The Supplier shall use Commercially Reasonable Efforts to ensure that sufficient manufacturing capacity to meet the Purchaser’s and/or Purchaser’s Nominated
Contract Manufacturer’s (as the case may be) requirements for API as shown in the Forecast Schedule is available at all times in accordance Section 3.3. The Purchaser and the Supplier shall regularly review and discuss the Manufacturing
capacity available at the Manufacturing Site in relation to the Forecast Schedule. In the event of a breakdown or fault in production which impacts the manufacturing capacity required hereunder or otherwise impacts the Manufacture of API for the
Purchaser, the Supplier shall notify the Purchaser as soon as reasonably practicable and shall use Commercially Reasonable Efforts to ensure a return to production as soon as possible. 
 ARTICLE 8 
 COMPLAINTS AND PRODUCT RECALL 
 8.1 Complaints and Product Recall. The Purchaser shall be solely responsible in accordance with Applicable Laws and regulations for the reporting to Regulators in
the territories in which the Purchaser is permitted to Manufacture and distribute Products pursuant to the License Agreement of any complaints and product recalls relating to Product which arise for any reason. 
 8.2 Manufacturing Events. The Supplier shall use Commercially Reasonable Efforts to advise, and shall use Commercially Reasonable Efforts to compel [***] to
advise, the Purchaser of any occurrence or information which arises out of the Manufacturing activities that has or could reasonably be expected to have adverse regulatory compliance and/or reporting consequences concerning API and/or Product within
forty-eight (48) hours of becoming aware of such information, and, subject to the Supplier’s confidentiality obligations to [***] (which the 
  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  

 13 

 
Supplier shall use Commercially Reasonable Efforts to compel [***] to waive), promptly furnish copies of any related information or reports to the Purchaser.
In addition to the foregoing, the Supplier shall use Commercially Reasonable Efforts to notify, and shall use Commercially Reasonable Efforts to compel [***] to notify, the Purchaser of any problem related to the Manufacture of API under this
Agreement within forty-eight (48) hours of becoming aware of such problem, including: 
 (a) where any API or its labelling may have been
mistaken for or applied to another product; or 
 (b) where any API may be affected by bacteriological or other contamination, significant
chemical, physical or other change or deterioration or stability failures; or 
 (c) where any API is the subject of a complaint by a Third
Party or customer in circumstances where this may impact API Manufactured for the Purchaser under this Agreement; or 
 (d) where any API may
not comply with the Specifications therefor. 
 8.3 Recall Strategy. If any of the circumstances described in Section 8.2 arise, at the
Purchaser’s written request, the Supplier shall use Commercially Reasonable Efforts to take, and shall use Commercially Reasonable Efforts to compel [***] to take, all such acts as the Purchaser may reasonably direct in writing. If the
Purchaser or any Regulator deems that a Product recall is required, the recall strategy shall be developed in good faith by the Parties and the Supplier shall use Commercially Reasonable Efforts to follow, and shall use Commercially Reasonable
Efforts to compel [***] to follow, timing requirements. The reasonable and documented costs of any such action agreed upon by the Parties as a result of the circumstances described in Section 8.2, or of any such recall under this
Section 8.3, shall be borne by the Supplier only in the event and to the extent the need for the action is the result of a failure on the part of the Supplier to comply with its obligations under this Agreement, and if not the result of a
failure of the Supplier shall be borne by the Purchaser. 
 8.4 Complaint Investigations. Upon notification from the Purchaser that it has received a
complaint in respect of the Product which the Purchaser reasonably believes is due to API, upon the Purchaser’s written request, the Supplier shall use Commercially Reasonable Effort to follow, and shall use Commercially Reasonable Efforts to
compel [***] to conduct, all such necessary internal investigations as may be reasonably necessary to determine the validity of such complaint. The findings of any such investigations shall be reported in writing to the Purchaser 
  
 *Indicates that certain information contained herein has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 14 

 
within five (5) Business Days of completion of the investigation, provided that the Purchaser shall be kept informed periodically as the investigation
progresses. The Purchaser shall thereafter respond to the complainant and provide a written copy of such response to the Supplier and the Supplier shall thereupon use Commercially Reasonable Efforts to carry out, and shall use Commercially
Reasonable Efforts to compel [***] to carry out, any actions which the Purchaser may reasonably require in connection therewith. The reasonable and documented costs of any such investigation or other action which the Purchaser requires to be
undertaken pursuant to this Section 8.4 shall be borne by the Supplier in the event and to the extent that the need for such action is the result of a failure on the part of the Supplier to comply with its obligations under this Agreement, and
if not the result of a failure of the Supplier shall be borne by the Purchaser. 
 ARTICLE 9 
 REJECTION AND REPLACEMENT OF DEFECTIVE API 
 9.1
Testing. Upon receipt of each Delivery under this Agreement, the Purchaser or Purchaser’s Nominated Contract Manufacturer (as applicable) shall carry out testing and/or control for such Delivery and shall report any adverse findings to
the Supplier pursuant to Section 9.3. API delivered to the Purchaser or Purchaser’s Nominated Contract Manufacturer will be deemed accepted by the relevant recipient if it fails to carry out such testing obligations pursuant to this
Section 9.1 or if no notification is made to the Supplier pursuant to Section 9.3 within the time period set out in Section 9.2, provided that notwithstanding acceptance of API pursuant to this Section 9.1 the Supplier shall
remain liable to the Purchaser under the terms of this Agreement for any defect or failure of API to comply with the terms of this Agreement. 
 9.2
Nonconformance. The Purchaser or Purchaser’s Nominated Contract Manufacturer (as applicable) shall have the right exercisable within thirty (30) days after Delivery to reject API or any part thereof contained in such Delivery if,
having carried out the relevant testing as prescribed in Section 9.1, or it becomes aware that any such API does not conform in quality or quantity or is otherwise defective with respect to the Specifications and all other terms of this
Agreement or the specific Firm Order or if API is not in Good Condition. 
 9.3 Rejection. In the event of any rejection of API pursuant to
Section 9.2: 
 (a) The Purchaser shall notify the Supplier in writing; 
 (b) The payment obligation in relation to any such delivery shall be suspended forthwith pending resolution of the dispute in accordance with this
Section; 
  
 *Indicates that certain information contained herein has been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 15 

 (c) The Parties shall immediately use their respective Commercially Reasonable Efforts to agree whether
or not the delivery in question complies with the Specifications; and 
 (d) The Supplier shall be entitled at all reasonable times to inspect
and/or analyze the delivery in question. 
 9.4 Independent Laboratory. The Parties shall use all Commercially Reasonable Efforts to resolve any
dispute that may arise pursuant to this Section but if the Parties fail to agree within thirty (30) days of notification to the Supplier pursuant to Section 9.3, whether any delivery of API supplied to the Purchaser hereunder is defective
or may be rejected for any other reason set out in Section 9.2, the dispute shall be determined by the Independent Laboratory and the decision of the Independent Laboratory shall be final and binding on the Parties. The Independent Laboratory
shall act as an expert and not as an arbitrator and (unless the Independent Laboratory otherwise determines) its fees shall be borne by the party against whom the Independent Laboratory’s decision is given. 
 9.5 API Agreed or Determined to be Nonconforming. If the Supplier agrees or the Independent Laboratory finds that any delivery of API is defective or may
otherwise be rejected in accordance with Section 9.2, without prejudice to any other rights under this Agreement that the Purchaser may have against the Supplier: 
 (a) The Supplier shall promptly collect at its own expense any rejected API from the Purchaser; and 
 (b) The
Supplier shall, in addition, promptly reimburse the Purchaser in respect of any reasonable and documented out-of-pocket costs (including without limitation freight, clearance, duty and storage) incurred by the Purchaser in respect of the defective
delivery, and replace the API with new API that strictly complies with the Specifications and all other requirements of the Agreement. 
 9.6 API
Determined to be Conforming. If a Delivery of API is found by the Independent Laboratory to comply with the requirements of Section 9.2, the Purchaser shall pay for such Delivery in accordance with the payment provisions contained in this
Agreement. 
  
 *Indicates that certain information contained herein has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 16 

 ARTICLE 10 
 QUALITY ASSURANCE; REGULATORY COMPLIANCE; AUDITS AND 
 INSPECTION; PRODUCT LICENSE; MANUFACTURING
LICENSE; 
 DOCUMENTATION AND REPORTS 
 10.1 Quality Assurance. The Supplier shall use Commercially Reasonable Efforts to provide, and shall use Commercially Reasonable Efforts to compel [***] to provide, to the Purchaser such documentation and information as may be
reasonably necessary for the Purchaser to evaluate and assess on an ongoing basis the quality assurance testing, cGMPs, manufacturing processes, and manufacturing controls relating to the API. Without limiting the foregoing, the Supplier shall use
Commercially Reasonable Efforts to compel [***] to comply with the quality requirements set forth in the [***] Agreement and use Commercially Reasonable Efforts to procure the right for the Purchaser to have the same access and information with
respect to such requirements as the Supplier has under the [***] Agreement. 
 10.2 Regulatory Compliance. The Supplier shall use Commercially
Reasonable Efforts to provide, and shall use Commercially Reasonable Efforts to compel [***] to provide, to the Purchaser such documentation and information as may be reasonably necessary for the Purchaser to comply on an ongoing basis with the
Purchaser’s regulatory obligations with respect to the API and the Product. Without limiting the foregoing, the Supplier shall use Commercially Reasonable Efforts to compel [***] to comply with the regulatory compliance requirements set forth
in the [***] Agreement and use Commercially Reasonable Efforts to procure the right for the Purchaser to have the same access and information with respect to such requirements as the Supplier has under the [***] Agreement. 
 10.3 Audits and Inspection. The Supplier shall use Commercially Reasonable Efforts to procure the right for the Purchaser to have the same audit and inspection
rights of [***] as the Supplier has with respect to [***] pursuant to the [***] Agreement. If the Supplier is unable to procure such rights, the Purchaser may direct the Supplier to carry out such audits and inspection to which the Supplier is
entitled under the [***] Agreement on the Purchaser’s behalf and the Supplier, subject to the Supplier’s confidentiality obligations to [***] (which the Supplier shall use Commercially Reasonable Efforts to compel [***] to waive), shall
report in writing its findings within ten (10) Business Days of completing the audit or inspection; the Purchaser will notify the Supplier in writing of any adverse observations within ninety (90) calendar days of the Purchaser’s
receipt of the Supplier’s report and the Supplier will use Commercially Reasonable Efforts to address with [***] such observations to the reasonable satisfaction of the Purchaser, including resolving a dispute with [***] by appeal to a Third
Party in accordance with the [***] Agreement. 
  
 *Indicates that certain
information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 17 

 10.4 Product License. The Purchaser shall be responsible for the registration of the Products with all relevant
Regulators in the jurisdictions in which the Purchaser may distribute Products pursuant to the License Agreement, and the Supplier shall provide such assistance (at the Purchaser’s expense) as the Purchaser may reasonably request in connection
therewith insofar as such assistance relates to the Manufacture of API and/or performance of this Agreement by the Supplier for supply by the Supplier to the Purchaser or Purchaser’s Nominated Contact Manufacturer (as applicable). 

10.5 Manufacturing Licenses. The Supplier shall use Commercially Reasonable Efforts to compel [***] to obtain and maintain in full force and effect for the
duration of this Agreement the Manufacturing License and all necessary permits, licenses, approvals and authorizations required under Applicable Laws to enable [***] to Manufacture and supply API to the Supplier. 
 10.6 Documentation and Reports. The Supplier shall use Commercially Reasonable Efforts to compel [***] to: 
 (a) complete and maintain (and ensure that any authorized subcontractors complete and maintain) the documentation relating to the Manufacture of each
batch of API in accordance with cGMPs and retain such documentation for a minimum period of six (6) years after release of API; 
 (b)
notify the Supplier, who will then notify Purchaser, of any batch failures, process deviations and any out-of-specification results which arise under Manufacture of Product as provided for in this Agreement; 
 (c) complete and maintain all records and reporting requirements relating to controlled drugs as may be applicable; and 
 (d) complete and lodge with the appropriate authorities where required all documentation relating to the export of API where Delivery involves export from
the country of Manufacture. 
 ARTICLE 11 
 CONFIDENTIALITY 
 11.1 Confidentiality. The Parties agree that during the Term, and for a period of five
(5) years after this Agreement expires or terminates, a Party receiving Confidential Information of the other Party shall (a) maintain in confidence such Confidential Information to the same extent 
  
 *Indicates that certain information contained herein has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 18 

 
such Party maintains its own proprietary information of similar kind and value (but at a minimum each Party shall use Commercially Reasonable Efforts to
maintain Confidential Information in confidence); (b) not disclose such Confidential Information to any Third Party without prior written consent of the Disclosing Party, except for disclosures to its sublicensees and commercial partners for
Products who agree to be bound by obligations of non-disclosure and non-use at least as stringent as those contained in this Article 11; and (c) not use such Confidential Information for any purpose except those purposes permitted by this
Agreement. Notwithstanding the foregoing, the Purchaser’s confidentiality obligations with respect to [***] Confidential Information received by the Purchaser in connection with the Parties’ performance of this Agreement shall continue
until three (3) years after the termination or expiration of the [***] Agreement; provided, in no event shall such confidentiality obligations extend past the later of (y) five (5) years after this Agreement expires or terminates, or
(z) April 1, 2022. 
 11.2 Authorized Disclosure. Notwithstanding any other provision of this Agreement, the Receiving Party may disclose
Confidential Information of the Disclosing Party to a Third Party: (a) to the extent and to the Persons as required by any Applicable Law, legal process or court order, or an applicable disclosure requirement of any Regulator, the U.S.
Securities and Exchange Commission (“SEC”), the Nasdaq market or any other securities exchange or market; or (b) to the extent necessary to exercise the rights granted to or retained by the Receiving Party under this Agreement
or otherwise establishing rights or enforcing obligations under this Agreement; provided, however, that the Receiving Party shall provide prior notice of such intended disclosure to the Disclosing Party if possible under the circumstances and shall
disclose only such Confidential Information of the Disclosing Party as is reasonably required to be disclosed. 
 11.3 Disclosure of Agreement. The
Parties agree that the material terms of this Agreement shall be considered Confidential Information of both Parties, subject to the special authorized disclosure provisions set forth below in this Section 11.3 (in lieu of the authorized
disclosure provisions set forth in Section 11.2, to the extent of any conflict) and without limiting the generality of the definition of Confidential Information set forth in Section 1.8. The Parties will mutually agree the text of a press
release announcing the execution of this Agreement. Thereafter, if either Party desires to make a public announcement concerning the terms of this Agreement, such Party shall give reasonable prior advance notice of the proposed text of such
announcement to the other Party for its prior review and approval, such approval not to be unreasonably withheld. A Party shall not be required to seek the permission of the other Party to repeat or disclose any information as to the terms of this
Agreement that has already been publicly disclosed by such Party in accordance with the foregoing or by the other Party, or any 
  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  

 19 

 
similar or comparable information. Either Party may disclose the terms of this Agreement to such Party’s existing investors, lenders, directors and
professional advisors and to potential investors, lenders, acquirors or merger partners and their professional advisors who are bound by written or professional obligations of non-disclosure and non-use that are at least as stringent as those
contained in this Article 11 or are customary for such purpose. Each Party acknowledges that the other Party may be obligated to file a copy of this Agreement with the SEC with its next quarterly report on Form 10-Q, annual report on Form 10-K or
current report on Form 8-K or with any registration statement filed with the SEC pursuant to the Securities Act of 1933, as amended, and each Party shall be entitled to make such filings, provided, however, that the filing Party requests (to the
extent legally permitted) confidential treatment of the terms hereof for which confidential treatment is customarily sought, to the extent such confidential treatment is reasonably available to such Party under the circumstances then prevailing. In
the event of any such filing, the filing Party will provide the other Party with a copy of the Agreement marked to show provisions for which the filing Party intends to seek confidential treatment and shall reasonably consider the other Party’s
timely comments thereon. 
 11.4 Unauthorized Use. If either Party becomes aware or has Knowledge of any unauthorized use or disclosure of the other
Party’s Confidential Information, it shall promptly notify the other Party of such unauthorized use or disclosure. 
 11.5 Return of Confidential
Information. Upon termination of this Agreement, the Receiving Party shall promptly return all of the Disclosing Party’s Confidential Information, including all reproductions and copies thereof in any medium (except that the Receiving Party
may retain one copy for its legal files) except as otherwise reasonably necessary to exercise the Receiving Party’s surviving rights under this Agreement. 
 ARTICLE 12 
 FORCE MAJEURE EVENT 
 12.1 General. Neither Party shall be liable to the other on account of any failure to perform or on account of any delay in performance of any obligation under this Agreement (excluding payment obligations), if
and to the extent that such failure or delay shall be due to a cause beyond the control of the relevant Party and which, by the exercise of its Commercially Reasonable Efforts of diligence and care, such Party could not reasonably have been expected
to avoid (a “Force Majeure Event”). For the evidence of doubt, any failure to Deliver API pursuant to a Firm Order due to an order, injunction or any other action by a Regulator shall not constitute a Force Majeure Event. The Party
experiencing the delay and seeking relief under this Section 
  
 *Indicates that
certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 20 

 
shall promptly notify the other Party of the delay and use Commercially Reasonable Efforts to overcome such delay. The Party affected shall promptly notify
in writing the non-affected Party of the specific causes beyond the control of the affected Party and the probable duration of the delay, and that Party shall be excused from the performance of such obligation to the extent such performance is
necessarily prevented, hindered or delayed thereby during the continuance of any such happening or event. This Agreement, insofar as it relates to such obligation, shall be deemed suspended so long as and to the extent that such cause delays the
performance of any Force Majeure Event obligation. 
 12.2 Termination; Transition. If as a result of the conditions referred to in Section 12.1,
the Supplier is unable to fully perform its obligations for a period of ninety (90) days, the Purchaser shall have the right to terminate this Agreement upon thirty (30) days prior notice to the Supplier. In the event the Purchaser
terminates this Agreement as provided in this Section 12.2, the Supplier agrees to use Commercially Reasonable Efforts to assist the Purchaser to transfer the Manufacture of the Products to any other facility or facilities selected by the
Purchaser, in its sole discretion. 
 ARTICLE 13 
 REPRESENTATIONS AND WARRANTIES 
 13.1 Mutual Representations and Warranties. Each Party hereby represents and
warrants to the other Party as of the Effective Date that: 
  

	 	(a)	such Party is a corporation or entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation and has full corporate power and
authority to execute and deliver this Agreement and to carry out the provisions hereof; 

  

	 	(b)	such Party is duly authorized, by all requisite corporate action, to execute and deliver this Agreement and to carry out the provisions hereof, and the Person executing this
Agreement on behalf of such Party is duly authorized to do so by all requisite corporate action; 

  

	 	(c)	except as set forth in the License Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal,
state or local governmental authority is required on the part of such Party in connection with the valid execution, delivery and performance of this Agreement, except where the failure to obtain any of the foregoing could not, individually or in the

 aggregate, reasonably be expected to materially adversely affect such Party’s ability to consummate the transactions
contemplated herein or perform its obligations hereunder; 
  
 *Indicates that
certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 21 

	 	(d)	this Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms, except as such enforceability may be limited by bankruptcy,
insolvency, reorganization, moratorium and similar laws; and 

  

	 	(e)	the execution, delivery and performance by it of this Agreement and its compliance with the terms and provisions of this Agreement does not and will not, except as set forth in the
License Agreement, (i) conflict with or result in a violation or breach of any of the terms, conditions or provisions of its certificate or articles of incorporation or by-laws (or other comparable corporate charter documents);
(ii) conflict with or result in a violation or breach of any term or provision of any law or order applicable to it; or (iii) (A) conflict with or result in a violation or breach of, (B) constitute (with or without notice or
lapse of time or both) a default under, (C) require it to obtain any consent, approval or action of, make any filing with or give any notice to any Person as a result or under the terms of, any contract, instrument or license to which it is a
party or by which any of its assets and properties is bound; except, in the case of (i), (ii) and (iii) above, which could not, individually or in the aggregate, reasonably be expected to materially adversely affect its ability to
consummate the transactions contemplated herein or perform its obligations hereunder. 

  

	 	13.2	Additional Supplier Representations and Warranties. The Supplier represents and warrants that: 

  

	 	(a)	To fulfil its obligations under this Agreement, the Supplier has allocated and will allocate resources sufficient to perform its obligations under this Agreement.

  

	 	(b)	The Supplier will convey to Purchaser the same title that the Supplier receives from [***] to the API supplied hereunder. 

  

	 	(c)	The Manufacture, generation, processing, distribution, transport, treatment, storage, disposal and other handling of any API until delivery to a carrier or freight forwarder shall
(i) be in accordance with and conform to the Specifications and cGMPs, (ii) be in accordance with and conform to any applicable standards specified by the United States Pharmacopeia and Pharmacopeia Forum and the European Pharmacopeia and
Pharmacopeial Forum, and (iii) otherwise conform to any provisions of the 

  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 22 

 
Regulatory Acts or any Applicable Laws not reflected in cGMPs. The API will strictly comply with the Specifications, shall be free from defects in materials
and workmanship and shall not be adulterated or misbranded within the meaning of applicable Regulatory Acts or the United States Federal Food, Drug, and Cosmetic Act. At the time of Delivery, the API shall be in Good Condition. THE REPRESENTATIONS
AND WARRANTIES PROVIDED IN THIS AGREEMENT DO NOT APPLY TO PRODUCTS TO THE EXTENT THAT, AFTER SHIPMENT, OCCURRENCES AFFECTING OR ALTERING THE PRODUCTS AFTER THEY ARE DELIVERED TO THE CARRIER, OR ACTIONS TAKEN OR FAILED TO BE TAKEN AFTER THE PRODUCTS
WERE SHIPPED, THE PRODUCTS FAIL TO CONFORM TO SPECIFICATIONS. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 13, THE SUPPLIER DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE. 
 ARTICLE 14 
 LIABILITY AND INDEMNIFICATION 
 14.1 Indemnity by the Supplier. Subject to Section 14.4
below, the Supplier hereby agrees to indemnify, defend and hold harmless the Purchaser and each Purchaser Affiliate who receives a Product subject to indemnity hereunder and their respective directors, officers, employees and agents (each a
“Purchaser Indemnitee”) from and against all losses, damages, costs, penalties, liabilities (including strict liabilities), judgements, amounts paid in settlement, fines and expenses (including court costs and reasonable fees of
attorneys and other professionals) (“Losses”) arising from a Third Party Claim (a) for bodily injury, death and property damage caused by: (i) defects inherent in the API at the time of delivery by [***] to Supplier;
(ii) defective API information (including any materials or samples thereof) submitted by [***] to the Supplier; or (iii) the negligence or wilful misconduct or wrongdoing of the Supplier or (b) arising with respect to any breach or
non-performance of any of the Supplier’s covenants, obligations, representations or warranties under this Agreement. The foregoing indemnification obligations shall not apply in each case to the extent any particular Loss is a direct result of
(i) the negligence or intentional misconduct of a Purchaser Indemnitee, or (ii) any matter for which the Purchaser is obligated to indemnify the Supplier pursuant to Section 14.2 herein. Nothing in this Section 14.1 or
Section 14.2 below shall be construed to limit, and these provisions shall be in addition to, any indemnification provision, in any other agreement between the Parties. 
 14.2 Indemnity by the Purchaser. Subject to Section 14.4 below, the Purchaser shall indemnify, defend and hold the Supplier and Supplier Affiliates an d their respective directors, 
  
 *Indicates that certain information contained herein has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 23 

 
officers, employees and agents (each a “Supplier Indemnitee”) harmless from and against all Losses arising from any Third Party Claim
(a) for bodily injury, death or property damage caused by: (i) the distribution or marketing of Products by the Purchaser; or (ii) the negligence or wilful misconduct or wrongdoing of the Purchaser, or (b) arising with respect to
any breach or non-performance of any of the Purchaser’s covenants, obligations, representations or warranties under this Agreement. The foregoing indemnification obligations shall not apply in each case to the extent any particular Loss is a
direct result of the negligence or intentional misconduct of the Supplier Indemnitee, or (ii) any matter for which the Supplier is obligated to indemnify the Purchaser pursuant to Section 14.1 above. Nothing in this Section 14.2 or
Section 14.1 above shall be construed to limit, and these provisions shall be in addition to, any indemnification provision in and any other agreement between the Parties. 
  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 
  

 24 

	 	14.3	Procedures. 

 (a) In the case of a Third Party Claim
made by any Person who is not a Party to this Agreement (or an Affiliate thereof) as to which a Party (the “Indemnitor”) may be obligated to provide indemnification pursuant to this Agreement, such Party seeking indemnification
hereunder (the “Indemnitee”) will notify the Indemnitor in writing of the Third Party Claim (and specifying in reasonable detail the factual basis for the Third Party Claim and, to the extent known, the amount of the Third Party
Claim) reasonably promptly after becoming aware of such Third Party Claim; provided, however, that failure to give such notification will not affect the indemnification provided hereunder except to the extent the Indemnitor shall have been actually
prejudiced as a result of such failure. 
 (b) If a Third Party Claim is made against the Indemnitee and the Indemnitor acknowledges in
writing its obligation to indemnify the Indemnitee therefor, the Indemnitor will be entitled, within one hundred twenty (120) days after receipt of written notice from the Indemnitee of the commencement or assertion of any such Third Party
Claim, to assume the defense thereof (at the expense of the Indemnitor) with counsel selected by the Indemnitor and reasonably satisfactory to the Indemnitee, for so long as the Indemnitor is conducting a good faith and diligent defense. Should the
Indemnitor so elect to assume the defense of a Third Party Claim, the Indemnitor will not be liable to the Indemnitee for any legal or other expenses subsequently incurred by the Indemnitee in connection with the defense thereof; provided, however,
that if under applicable standards of professional conduct a conflict of interest exists between the Indemnitor and the Indemnitee in respect of such claim, such Indemnitee shall have the right to employ separate counsel (which shall be reasonably
satisfactory to the Indemnitor) to represent such Indemnitee with respect to the matters as to which a conflict of interest exists and in that event the reasonable fees and expenses of such separate counsel shall be paid by such Indemnitor;
provided, further, that the Indemnitor shall only be responsible for the reasonable fees and expenses of one separate counsel for such Indemnitee. If the Indemnitor assumes the defense of any Third Party Claim, the Indemnitee shall have the right to
participate in the defense thereof and to employ counsel, at its own expense, separate from the counsel employed by the Indemnitor. If the Indemnitor assumes the defense of any Third Party Claim, the Indemnitor will promptly supply to the Indemnitee
copies of all correspondence and documents relating to or in connection with such Third Party Claim and keep the Indemnitee informed of developments relating to or in connection with such Third Party Claim, as may be reasonably requested by the

  
 *Indicates that certain information contained herein has been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 25 

 
Indemnitee (including, without limitation, providing to the Indemnitee on reasonable request updates and summaries as to the status thereof). If the
Indemnitor chooses to defend a Third Party Claim, all Indemnitees shall reasonably cooperate with the Indemnitor in the defense thereof (such cooperation to be at the expense, including reasonable legal fees and expenses, of the Indemnitor). If the
Indemnitor does not elect to assume control of the defense of any Third Party Claim within the one hundred twenty (120) day period set forth above, or if such good faith and diligent defense is not being or ceases to be conducted by the
Indemnitor, the Indemnitee shall have the right, at the expense of the Indemnitor, after three (3) Business Days notice to the Indemnitor of its intent to do so, to undertake the defense of the Third Party Claim for the account of the
Indemnitor (with counsel selected by the Indemnitee), and to compromise or settle such Third Party Claim, exercising reasonable business judgment; provided, however, that the Indemnitee shall not compromise or settle such Third Party Claim without
the Indemnitor’s prior written consent (which consent shall not be unreasonably withheld) if such compromise or settlement would result in an admission or liability or loss of right by the Indemnitor or payment by the Indemnitor. The Indemnitor
agrees to reasonably cooperate with the Indemnitee in such defense, at the Indemnitor’s expense, including being joined as a necessary party. 
 (c) If the Indemnitor acknowledges in writing its obligation to indemnify the Indemnitee for a Third Party Claim, the Indemnitee will agree to any settlement, compromise or discharge of such Third Party Claim that the Indemnitor may
recommend that by its terms obligates the Indemnitor to pay the full amount of Losses (whether through settlement or otherwise) in connection with such Third Party Claim and unconditionally and irrevocably releases the Indemnitee completely from all
liability in connection with such Third Party Claim; provided, however, that, without the Indemnitee’s prior written consent, the Indemnitor shall not consent to any settlement, compromise or discharge (including the consent to entry of any
judgment), and the Indemnitee may refuse in good faith to agree to any such settlement, compromise or discharge, that provides for injunctive or other non-monetary relief affecting the Indemnitee. If the Indemnitor acknowledges in writing its
obligation to indemnify the Indemnitee for a Third Party Claim, the Indemnitee shall not (unless required by law) admit any liability with respect to, or settle, compromise or discharge, such Third Party Claim without the Indemnitor’s prior
written consent (which consent shall not be unreasonably withheld). 
  
 *Indicates
that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 26 

 14.4 Limitations. Notwithstanding any provision of this Agreement to the contrary, in no event shall either Party
be liable to the other, or have any obligation to indemnify any Purchaser Indemnitee or Supplier Indemnitee, as the case may be, for any consequential or indirect damages or Losses including any loss of profits suffered by the Purchaser or the
Supplier, however caused and on any theory of liability, regardless of any failure of essential purpose of any remedy available under this Agreement. The foregoing limitation on liability shall not be applicable to consequential or indirect damages
or Losses, including without limitation, lost profits incurred by the Indemnitee as a direct result of any failure by the Indemnitor to perform its obligations under this Agreement that the Indemnitee can demonstrate is due to wilful misconduct or
gross negligence by the Indemnitor or any of its employees. 
 ARTICLE 15 
 INSURANCE 
 Each Party shall at all times maintain in full force and effect, with financially
sound and reputable carriers reasonably satisfactory to the other Party, product liability, property, and fidelity insurance in such amounts and with such scope of coverage as are adequate to cover such Party’s obligations under this Agreement
and as are appropriate companies of like size, taking into account the nature of API to be manufactured hereunder. 
 ARTICLE 16

 TERM; TERMINATION; REMEDIES 
 16.1
General. 
 (a) This Agreement shall commence on the Effective Date and will continue until December 31, 2012 (the
“Initial Term”). Unless terminated pursuant to Sections 12.2, 16.1(b), 16.1(c), 16.1(d), 16.4 or 16.7, this Agreement shall automatically renew for successive terms of three (3) years (each, a “Renewal Term”).
The period from the Effective Date until the termination of the Agreement is the “Term”. 
 (b) The Purchaser may terminate
this Agreement by delivery of a one hundred eighty (180) days advance, written notice. 
 (c) The Supplier may terminate this Agreement
by delivery of a one hundred eighty (180) days advance, written notice. 
  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 27 

 (d) Either Party may terminate this Agreement or any Firm Orders by delivery of written notice following
expiration or termination of the License Agreement or the [***] Agreement. 
 16.2 Manufacturing Site. The Purchaser may terminate this Agreement on
thirty (30) days written notice if [***] changes the Manufacturing Site at which API is Manufactured or the process used in the Manufacture of API. Any such termination pursuant to this Section 16.2 shall not be deemed to be due to a
breach by the Supplier. 
 16.3 Supplier Material Default. “Supplier Material Default” shall mean the occurrence of any of the events
listed below, regardless of whether the occurrence is voluntary or involuntary; provided, however, that none of the following occurrences shall constitute a “Supplier Material Default” to the extent such occurrence is a direct
result of a breach by the Purchaser of a representation, warranty or covenant hereunder, any failure by the Purchaser to comply with Applicable Laws to the extent they pertain to the Products or the Regulatory Acts, a Purchaser Material Default, the
Supplier’s compliance with an order of a Regulator directed to the Supplier specifically regarding its compliance with cGMPs, the Regulatory Acts, or Applicable Laws, or a Force Majeure Event: 
 (a) an assignment or attempted assignment of this Agreement or the rights or obligations arising hereunder by the Supplier, in violation of this
Agreement; 
 (b) insolvency or general failure of the Supplier to pay its debts as they become due; entrance of the Supplier into
receivership or any arrangement with creditors generally; filing of a voluntary or involuntary petition or other action or proceeding for bankruptcy or reorganization or dissolution or winding-up of the Supplier; a general assignment for the benefit
of the Supplier’s creditors; or a foreclosure or sale of a material part of the Supplier’s assets by or for the benefit of any creditor or governmental agency; or 
 (c) a material breach or failure by the Supplier with respect to any material obligation or covenant under this Agreement, including a failure to Deliver
API pursuant to a Firm Order or a failure to maintain the Eighteen Month Supply at the amount required under Section 3.3, that is not remedied by the Supplier within thirty (30) days after receiving notice thereof or, if such breach or
failure is susceptible of cure but cannot be reasonably cured within thirty (30) days, unless the Supplier in good faith promptly commences pursuing such cure and diligently and continually does so but is delayed in completion by factors beyond
its control after the use of Commercially Reasonable Efforts (but in no event to exceed ninety (90) days from the date of the Purchaser’s notice). 
  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  

 28 

 16.4 Other Supplier Default. “Other Supplier Default” shall mean the breach or failure by the
Supplier with respect to any obligation, covenant, representation, warranty or condition under this Agreement that is not remedied by the Supplier within thirty (30) days after receiving written notice thereof from the Purchaser, other than a
Supplier Material Default, or if such breach or failure is susceptible of cure but cannot be reasonably cured within thirty (30) days, unless the Supplier in good faith promptly commences pursuing such cure and diligently and continually does
so but in no event to exceed sixty (60) days from the date of the Purchaser’s notice. Notwithstanding the foregoing, none of the foregoing occurrences shall constitute an Other Supplier Default to the extent such occurrence is a direct
result of (a) a breach by the Purchaser of a representation, warranty or covenant hereunder, (b) any failure by the Purchaser to comply with the Applicable Laws or Regulatory Acts or to perform any of its obligations under this Agreement,
(c) the Supplier’s compliance with the Specifications or an order of a Regulator directed to the Supplier specifically regarding its compliance with cGMPs, the Regulatory Acts, or Applicable Laws, or (d) a Force Majeure Event.

 16.5 Effect of Supplier Default. 
 (a)
The Supplier Material Default. Upon the occurrence of a Supplier Material Default, the Purchaser shall have the right to (i) terminate this Agreement, in whole or in part, immediately or at such other date specified under this Agreement,
or (ii) terminate any Firm Order issued under this Agreement, in which case the Purchaser shall bear no liability with respect to the terminated Firm Order, including, without limitation, any expenses incurred by the Supplier in connection with
such terminated Firm Order. In either event, the Purchaser shall also be entitled to seek all other remedies available under law or in equity. 
 (b) Other Supplier Default. Upon the occurrence of an Other Supplier Default, the Purchaser shall have no right to terminate this Agreement, but the Purchaser shall have the right to seek all other remedies available under law.

 16.6 Purchaser Material Default. A “Purchaser Material Default” shall occur upon the Purchaser’s failure to
pay an amount specified in this Agreement due to the Supplier under this Agreement within fifteen (15) Business Days after receiving written notice thereof from the Supplier (such notice to be accompanied by copies of invoices, shipping
manifests and other relevant documentation supporting the Supplier’s claim for payment), other than the portion of 
  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  

 29 

 
any payment hereunder that is the subject of a pending good faith dispute identified by the Purchaser in a written notice delivered to the Supplier following
receipt of an invoice and before such payment is due to the Supplier. 
 16.7 Other Purchaser Default. “Other Purchaser Default”
shall mean the breach or failure by the Purchaser with respect to any obligation, covenant, representation, warranty or condition under this Agreement, other than a Purchaser Material Default, that is not remedied by the Purchaser within thirty
(30) days after receiving written notice thereof from the Supplier, or if such breach or failure is susceptible of cure but cannot be reasonably cured within thirty (30) days, unless the Purchaser in good faith promptly commences pursuing
such cure and diligently and continually does so, but in no event to exceed sixty (60) days from the date of the Supplier’s notice. 
 16.8
Effect of a Purchaser Default. 
 (a) Purchaser Material Default. Upon the occurrence of a Purchaser Material Default, the
Supplier shall have the right to terminate this Agreement immediately or at such other date specified under this Agreement and to seek all other remedies available under law or in equity. 
 (b) Other Purchaser Default. Upon the occurrence of an Other Purchaser Default, the Supplier shall have no right to terminate this Agreement, but
the Supplier shall have all rights to pursue all other remedies available under law. 
 16.9 Eighteen Month Supply. If the Eighteen Month Supply is
not at the time of termination the quantity required under Section 3.3, at the Purchaser’s written request, the Supplier shall Deliver at the time of termination API that strictly complies with the Specifications and all other requirements
of this Agreement to the Purchaser to the extent necessary to satisfy such deficiency in the Eighteen Month Supply. 
 16.10 Remedies. Except as
expressly set forth in this Agreement, none of the remedies set forth in this Agreement are intended to be exclusive, and each Party shall have available to it all remedies available under law or in equity. The Parties specifically acknowledge and
agree that the Purchaser will have available the remedy of specific performance under this Agreement upon a Supplier Material Default. 
 16.11 Injunctive
Relief. In the event that either the Supplier or the Purchaser breaches or threatens to breach any provision of Article 11 of this Agreement, the Parties agree that 
  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 
  

 30 

 
irreparable harm to the other Party should be presumed and the damage to such Party would probably be very difficult to ascertain and would be inadequate.
Accordingly, in the event of such circumstances, each of the Supplier and the Purchaser agree that, in addition to any other right and remedies available at law or in equity, the other Party shall have the right to obtain injunctive relief from any
court of competent jurisdiction. 
 ARTICLE 17 
 MISCELLANEOUS 
 17.1 Standard Forms. In all communications, the Purchaser and the Supplier may employ their
standard forms (including terms and conditions in purchase orders and purchase order acknowledgements), but nothing in those forms shall be construed to modify or amend the terms and conditions of this Agreement, and, in the case of any conflict
herewith, the terms and conditions of this Agreement shall control. 
 17.2 Notices. 
  

			
	 Notices to the Purchaser shall be addressed to:

		
		 	Inspire Pharmaceuticals, Inc.
		 	4222 Emperor Boulevard, Suite 200
		 	Durham, North Carolina 27703
		 	Attention: General Counsel
		 	Facsimile No.: 919-941-9797
		
	 With a copy to:
	 	Smith, Anderson, Blount,
		
		 	Dorsett, Mitchell & Jernigan, L.L.P.
		 	2500 Wachovia Capitol Center
		 	Raleigh, North Carolina 27601
		 	Attention: Christopher Capel
		 	Facsimile No.: 919-821-6800
	
	 Notices to the Supplier shall be addressed to:

		
		 	InSite Vision Incorporated
		 	965 Atlantic Avenue
		 	Alameda, California 94501
		 	Attention: Chief Executive Officer
		 	Facsimile No.: 510-865-5700

  
 *Indicates that certain information
contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 31 

			
	 With a copy to:
	 	O’Melveny & Myers LLP
		 	2765 Sand Hill Road
		 	Menlo Park, California 94025
		 	Attention: Tim Curry, Esq.
		 	Facsimile No.: 650-473-2601

 Either Party may change the address to which notices shall be sent by giving notice to the other Party in the
manner herein provided. Any notice required or provided for by the terms of this Agreement shall be in writing and shall be (i) sent via a reputable overnight courier service, or (ii) sent by facsimile transmission, in each case properly
addressed in accordance with the paragraphs above. The effective date of any notice shall be the actual date of receipt by the Party receiving the same. 
 17.3 Independent Contractors. The relationship between the Parties created by this Agreement is one of independent contractors and is not a joint venture, partnership or any similar arrangement. Neither Party shall have the power or
authority to bind or obligate the other except as expressly set forth in this Agreement. 
 17.4 Certain Remedies. Each Party acknowledges and agrees
that the other Party may be irreparably damaged if any of the provisions of this Agreement (other than provisions involving the payment of money) are not performed by a Party in accordance with their specific terms, and that any breach of, or
failure to perform or comply with, this Agreement by a Party may not be adequately compensated in all cases by monetary damages alone. Accordingly, in addition to any other right or remedy to which a Party may be entitled at law or in equity, it may
be entitled to enforce any provision of this Agreement (other than provisions involving the payment of money) by a decree of specific performance and to temporary, preliminary and permanent injunctive relief to prevent breaches or threatened
breaches of any of the provisions of this Agreement, without posting any bond or other undertaking. 
 17.5 Expenses. Unless otherwise provided
herein, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the Party that shall have incurred the same and the other Party shall have no liability relating thereto. 

 
 *Indicates that certain information contained herein has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 32 

 17.6 No Third Party Beneficiaries. No person or entity other than the Parties hereto and their respective
Affiliates, successors and permitted assigns shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement. 
 17.7 Entire Understanding. This Agreement, together with the Schedules and Exhibits hereto, constitutes and contains the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes any and all
prior negotiations, correspondence, understandings and agreements whether oral or written, between the Parties respecting the subject matter hereof and thereof. 
 17.8 Unintentional Omissions. The Parties acknowledge that they have expended substantial effort in preparing this Agreement and attempting to describe, in the Schedules hereto, as thoroughly and precisely as possible, Specifications
and other information. However, despite these efforts, the Parties acknowledge the possibility of involuntary or inadvertent omissions from the Schedules. The Parties will agree in writing to the changes to be made to the Schedules to add these
inadvertent or involuntary omissions and any such written agreement executed by the Parties shall serve as an amendment to this Agreement. 
 17.9
Transferability; Binding Effect. This Agreement may not be assigned or otherwise transferred (in whole or in part, whether voluntarily, by operation of law or otherwise) by either Party without the prior written consent of the other Party
(which consent shall not be unreasonably withheld); provided, however, that such consent shall not be required in connection with (a) assignment or transfer to an Affiliate of the Party; (b) a merger, consolidation or reorganization of the
Party, (c) a sale or transfer of all or substantially all of the voting stock, or all or substantially all of the assets, of the Party, or (d) a sale or transfer by the Party of all or substantially all of the assets of the Party with
respect to its program related to Products. Notwithstanding the foregoing, any such assignment or transfer to an Affiliate shall not relieve the assigning Party of its responsibilities for performance of its obligations under this Agreement. The
rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. Any attempted assignment not in accordance with this Agreement shall be void.

 17.10 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 33 

 17.11 Amendment. No amendment, modification or supplement of any provision of this Agreement shall be valid or
effective unless made in writing and signed by a duly authorized officer of each Party. 
 17.12 Severability. If any provision hereof should be held
invalid, illegal or unenforceable in any respect in any jurisdiction, the Parties hereto shall use reasonable efforts to substitute, by mutual written consent, valid provisions for such invalid, illegal or unenforceable provisions which valid
provisions in their economic effect are sufficiently similar to the invalid, illegal or unenforceable provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid provisions. In case such valid
provisions cannot be agreed upon, the invalid, illegal or unenforceable provisions of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provisions are of such essential importance
to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provisions. 
 17.13 Waiver. No provision of this Agreement shall be waived by any act or omission of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly
authorized officer of the waiving Party. 
 17.14 Survival. Articles 11, 13, 14, 16 and 17 and any other provision which by its terms specifically
shall so state, together with any obligation to make accrued but unpaid payments due hereunder, shall survive the termination or expiration of this Agreement until the last-to-expire of the longest statute of limitations governing any claims
relating to the performance of this Agreement. 
 17.15 No Strict Construction. This Agreement has been prepared jointly and shall not be strictly
construed against either Party. 
 17.16 Descriptive Headings; Schedules; Interpretation. 
 (a) The descriptive headings of this Agreement are for convenience only, and shall be of no force or effect in construing or interpreting any of the
provisions of this Agreement. 
 (b) All Schedules delivered pursuant to this Agreement shall be deemed part of this Agreement and
incorporated herein by reference, as if fully set forth herein. All provisions contained in any Schedule delivered by or on behalf of the Parties hereto, or in connection with the transactions contemplated hereby, are an integral part of this
Agreement. 
  
 *Indicates that certain information contained herein has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 34 

 (c) Words denoting the singular include the plural and vice versa; words denoting one gender include all
genders. 
 (d) References to the word “including” or “includes” are to be construed as “including without
limitation” and “includes without limitation”. 
 17.17 Counterparts; Facsimile Signatures. This Agreement may be executed in
counterparts and such counterparts taken together shall constitute one and the same agreement. This Agreement may be executed by facsimile signatures, which signatures shall have the same force and effect as original signatures. 
 17.18 Time of the Essence. Time shall be of the essence in relation to the performance of any and all of each Party’s obligations pursuant to this Agreement.

 17.19 Governing Law. This Agreement shall be governed and construed in accordance with the laws of the State of New York, without giving effect to
any choice of law provisions thereof. Prior to bringing a legal action against the other Party, such dispute shall be separately negotiated by the Parties hereto in good faith and all reasonable efforts undertaken to settle amicably such matters
before resorting to further legal recourse, as follows: upon the occurrence of a dispute between the Parties, including, without limitation, any breach of this Agreement or any obligation relating thereto, the matter shall be referred first to the
officers of the Supplier and the Purchaser having responsibility for the subject matter of the dispute, or their designees. The officers, or their designees, as the case may be, shall negotiate in good faith to resolve such dispute in a mutually
satisfactory manner for up to thirty (30) days. If such efforts do not result in mutually satisfactory resolution of the dispute, the matter shall be referred to the chief executive officers of the Supplier and the Purchaser, or their
designees. The chief executive officers, or their designees, as the case may be, shall negotiate in good faith to resolve such dispute in a mutually satisfactory manner for up to thirty (30) additional days, or such longer period of time to
which the chief executive officers may agree. Notwithstanding the foregoing, nothing in this Section 17.19 shall prevent a Party from seeking injunctive relief pursuant to Section 17.4. 
 [Signature Page Immediately Follows] 
  
 *Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  

 35 

 IN WITNESS WHEREOF, duly authorized representatives of the Parties duly executed this Agreement as of the Effective Date.

  

			
	INSPIRE PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Christy L. Shaffer

	Name:	 	Christy L. Shaffer
	Title:	 	President & CEO
	
	INSITE VISION INCORPORATED
		
	By:	 	 /s/ S. Kumar Chandrasekaran

	Name:	 	S. Kumar Chandrasekaran
	Title:	 	CEO

  
 *Indicates that certain
information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 36 

 Schedule 1 
 Specifications 
  

					
	 TEST
	  	 METHOD
	  	 SPECIFICATION

	 1. [***]
	  	[***]	  	[***]
			
	 2. [***]
	  	[***]	  	[***]
			
	 3. [***]
	  	[***]	  	[***]
			
	 4. [***]
	  	[***]	  	[***]
			
	 5. [***]
	  	[***]	  	[***]
			
	 6. [***]
	  	[***]	  	[***]
			
	 7. [***]
	  	[***]	  	[***]
			
	 8. [***]
	  	[***]	  	[***]
			
	 9. [***]
	  	[***]	  	[***]
			
	 10. [***]
	  	[***]	  	[***]

  
 *Indicates that certain information
contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 37 

 Schedule 2 
 Price 
 The price shall be the [***] the [***] Agreement (for the calendar year 2007 such cost is [***] of
API) plus [***]. 
  
 *Indicates that certain information contained herein has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 38Trademark License Agreement

 EXHIBIT 10.3 
 TRADEMARK LICENSE AGREEMENT 
 This TRADEMARK LICENSE AGREEMENT (this “Agreement”), dated as of
February 15, 2007 (the “Effective Date”), is made by and between Inspire Pharmaceuticals, Inc., a Delaware corporation having its principal office at 4222 Emperor Blvd., Suite 200, Durham, NC 27703 (“Inspire”),
and InSite Vision Incorporated, a Delaware corporation having its principal office at 965 Atlantic Ave., Alameda, CA 94501 (“InSite”). Inspire and InSite are each sometimes referred to individually as a “Party” and
together as the “Parties.” 
 RECITALS 
 WHEREAS, InSite and Inspire are entering into a license agreement (the “License Agreement”) contemporaneously with this Agreement, under which InSite is granting to Inspire the exclusive rights in the
Territory to certain patents, know-how and regulatory filings for the commercialization of Subject Products; 
 WHEREAS, InSite owns and has
the right to grant a license to the InSite Trademarks and the Domain Names described on Schedule 1 attached hereto; and 
 WHEREAS,
Inspire desires to obtain from InSite, and InSite desires to grant to Inspire, rights and licenses to use the InSite Trademarks and the Domain Names in connection with the marketing, commercialization and sale of Subject Products in the Territory
under the License Agreement. 
 NOW, THEREFORE, in consideration of the foregoing premises, the rights and benefits that they will each
receive in connection with the License Agreement, and the mutual representations, covenants and agreements contained herein, Inspire and InSite, intending to be legally bound, hereby agree as follows: 
 ARTICLE 1 
 DEFINITIONS

 1.1 Incorporated Definitions. Capitalized terms that are used in this Agreement but are not otherwise defined in this Agreement will have the
respective meaning ascribed to such terms in the License Agreement. 
 1.2 Additional Definitions. When used in this Agreement, whether in the
singular or plural, each of the following capitalized terms shall have the meanings set forth in this Section 1.2. 
 (a)
“AzaSite Trademark” means the trademark AzaSiteTM. 
 (b) “Domain Names” means the internet domain names
set forth in Schedule 1, such domain names being owned and registered by InSite. 
 (c) “Independent Sublicensee” has
the meaning set forth in Section 4.4. 
 (d) “InSite Trademarks” means the trademarks set forth in Schedule 1,
such marks being owned and registered by InSite. From and after the effective date of the assignment of the AzaSite Trademark by InSite to Inspire pursuant to Section 2.3(b) of 

 
the License Agreement, the term “InSite Trademarks” shall not include the AzaSite Trademark for any purpose under this Agreement. 
 (e) “Term” has the meaning set forth in Section 4.1. 
 ARTICLE 2 
 LICENSES AND EXCLUSIVITY 
 2.1 Licenses. 
 (a) Subject to the terms and
conditions of this Agreement, InSite hereby grants to Inspire a royalty-free, exclusive (even as to InSite and its Affiliates) right and license, with the right to grant sublicenses, to use the AzaSite Trademark and the Domain Names in connection
with the marketing, commercialization and sale of Subject Products in the Field in the Territory under the License Agreement. In connection with such license, InSite agrees immediately to cease any and all use of the Domain Names and to execute and
deliver such further and other documents and to perform such actions as may be necessary to enable Inspire to access and use the Domain Names under such license. 
 (b) Subject to the terms and conditions of this Agreement, InSite hereby grants to Inspire a royalty-free, non-exclusive right and license, with the right to grant sublicenses, to use the InSite Trademarks (other than
the AzaSite Trademark) in connection with the marketing, commercialization and sale of Subject Products in the Field in the Territory under the License Agreement. Notwithstanding the non-exclusive nature of the foregoing grant, InSite hereby
expressly covenants that it shall not, and shall cause its Affiliates and licensees not to, directly or indirectly: (x) use the InSite Trademarks in connection with the marketing, commercialization or sale of Subject Products in the Field in
the Territory; or (y) grant to any Third Party any right or license under the InSite Trademarks to conduct any of the activities set forth in the foregoing clause (x). 
 2.2 Sublicenses. Inspire may sublicense the rights granted under Section 2.1 only to sublicensees who will use the InSite Trademarks and the Domain Names in connection with the marketing, commercialization
and sale of Subject Products in the Field in the Territory under the License Agreement. All sublicenses granted hereunder must be in writing and must contain provisions that are not inconsistent with the terms and conditions of this Agreement. All
sublicenses shall include quality control standards at least as protective as those referenced under Section 3.1. 
 2.3 Use of Affiliates and Third
Party Contractors. The licenses granted under Section 2.1 include the right of Inspire to engage its Affiliates and Third Party contractors in exercising such rights and in carrying out its activities and obligations under this Agreement,
provided that (i) all such agreements with Third Party contractors must be in writing and must contain provisions that are not inconsistent with the terms and conditions of this Agreement and (ii) Inspire remains responsible for the
compliance with this Agreement by such Affiliates or Third Party contractors. 
 2.4 No Implied Grants. Except as expressly licensed hereunder,
neither Party grants any rights to the other Party under this Agreement, by implication or estoppel, under any of its intellectual property rights. 
  

 2 

 2.5 Registration of License. Notwithstanding anything to the contrary in Section 5.1, Inspire, at its
expense, may register the licenses granted under this Agreement in any country of the Territory. Upon request by Inspire, InSite agrees promptly to execute any “short form” licenses consistent with the terms and conditions of this
Agreement submitted to it by Inspire reasonably necessary to effect the foregoing registration in such country. 
 2.6 Notice. In connection with the
use of the InSite Trademarks, Licensee will mark the first prominent use of the InSite Trademark with the appropriate trademark symbol (“TM” or “®”, as set forth in Schedule 1 or as otherwise reasonably instructed by
InSite in writing) and will include the following legend in connection with such use: “[InSite Trademark] is the trademark of InSite Vision Incorporated and is being used by permission.” 
 ARTICLE 3 
 QUALITY CONTROL AND
RELATED MATTERS 
 3.1 Quality Control and Standards. Inspire shall adhere to such reasonable quality control standards that InSite may from time
to time promulgate and communicate to Inspire in writing with respect to the InSite Trademarks, and shall comply materially with all federal, state and local laws and regulations governing the use of the InSite Trademarks in connection with the
provision of Inspire Licensed Products. In order to confirm that Inspire’s use of the InSite Trademarks complies with this Section 3.1, InSite shall have the right upon written notice to require that Inspire submit to InSite a reasonable
number of representative samples of any Inspire Licensed Products or related materials bearing the InSite Trademarks. 
 3.2 Protection of the InSite
Trademarks. Inspire hereby acknowledges InSite’s rights in the InSite Trademarks and shall not at any time do or authorize to be done any action that would prejudice the validity or registration of the InSite Trademarks or the good will
associated therewith, including filing for, using or authorizing the use of any trademark (i) likely to cause consumer confusion with respect to the InSite Trademarks or (ii) containing “SITE” as a part. It is understood that
neither Inspire nor any of its Affiliates shall acquire or claim any independent right, title or interest in or to the InSite Trademarks by virtue of Inspire’s use of the InSite Trademarks as provided in this Agreement, it being the intention
of the Parties that all use of the InSite Trademarks by Inspire, and all goodwill associated therewith, shall at all times inure to the exclusive benefit of InSite. 
 ARTICLE 4 
 TERM AND TERMINATION 
 4.1 Term. Except as set forth in Section 5.13, unless earlier terminated by mutual agreement of the Parties in writing or pursuant to the provisions of this Article 4, this Agreement will become effective
as of the Effective Date and continue in full force and effect until the expiration or termination of the License Agreement in its entirety (the “Term”). 
 4.2 Bankruptcy or Insolvency. Either Party may, subject to the provisions set forth herein, terminate this Agreement by giving the other Party written termination notice if, at any time, the other Party shall:
(a) file in any court pursuant to any statute a petition for bankruptcy or insolvency, or for reorganization in bankruptcy, or for an arrangement or for the appointment of 

  

 3 

 
a receiver, trustee or administrator of such Party or of its assets; (b) be served with an involuntary petition against it, filed in any insolvency
proceeding, and such petition shall not be dismissed within sixty (60) days after the filing thereof; (c) propose or be a party to any dissolution; or (d) make an assignment for the benefit of its creditors. 
 4.3 Termination of License Agreement. If either Party terminates the License Agreement in its entirety pursuant to Section 10.2 or 10.3 thereof, then either
such terminating Party or the other Party may terminate this Agreement in its entirety concurrently with such termination by providing written notice thereof to the other Party. If either Party terminates the License Agreement with respect to a
particular country pursuant to Section 10.2 or 10.3 thereof, then either such terminating Party or the other Party may terminate this Agreement, solely with respect to such country, concurrently with such termination by providing written notice
thereof to the other Party. 
 4.4 Continuing Rights of Sublicensees. Upon any termination of any license rights granted to Inspire under this
Agreement, each sublicense previously granted by Inspire or any of its Affiliates under such license rights to any Person that is not an Affiliate of Inspire (each, an “Independent Sublicensee”) shall remain in effect and shall
become a direct license or sublicense, as the case may be, of such rights by InSite to such Independent Sublicensee, subject to (i) the Independent Sublicensee agreeing in writing to assume Inspire’s terms, conditions and obligations to
InSite under this Agreement as they pertain to the sublicensed rights, and (ii) Inspire remaining liable for any liability to the Independent Sublicensee incurred by Inspire prior to such termination. 
 4.5 Effect of Expiration or Termination. 
 (a)
Expiration or termination of this Agreement in its entirety pursuant to this Article 4 shall not (i) relieve a Party hereto of any obligation accruing to such Party prior to such termination, or (ii) result in the waiver of any right or
remedy by a Party hereto accruing to such Party prior to such termination. Upon termination of this Agreement in its entirety, all licenses granted to Inspire by InSite under this Agreement will terminate, and all rights therein will revert to
InSite. Inspire promptly shall cease, and cause its Affiliates and sublicensees (subject to Section 4.4) promptly to cease, any use of any InSite Trademarks and Domain Names in the Territory. 
 (b) Termination of this Agreement with respect to a particular country pursuant to this Article 4 shall not (i) relieve a Party hereto of any
obligation accruing to such Party prior to such termination, (ii) result in the waiver of any right or remedy by a Party hereto accruing to such Party prior to such termination, or (iii) result in the termination or modification of any
rights or obligations of a Party under the Agreement not involved in such termination. Upon termination of this Agreement with respect to a particular country, the licenses granted to Inspire by InSite under this Agreement solely with respect to
such country will terminate, and all such rights will revert to InSite. Inspire promptly shall cease, and cause its Affiliates and sublicensees (subject to Section 4.4) promptly to cease, any use of any InSite Trademarks in such country.

 (c) Notwithstanding anything to the contrary in this Agreement, the licenses granted to Inspire by InSite under this Agreement shall
continue during any period in which 

  

 4 

 
Inspire continues to have the right to sell Inspire Licensed Products under Sections 10.6(c) or 10.7(c) of the License Agreement solely in connection with
Inspire’s exercise of its rights as set forth in the License Agreement during such period. 
 ARTICLE 5 
 MISCELLANEOUS 
 5.1 Confidentiality. All secret,
confidential or proprietary information or data, whether provided in written, oral, graphic, video, computer or other form, provided by a Party to the other Party in connection with the activities contemplated by this Agreement is and will be deemed
under the License Agreement to be Confidential Information of the Party providing such information or data, subject to the limitations set forth in Section 1.15 thereof, and will be held in accordance with and subject to the terms of Article 8
thereof. The terms of this Agreement shall also be deemed Confidential Information of each Party under the License Agreement, except to the extent disclosed pursuant to Section 8.4 thereof. 
 5.2 Assignment. This Agreement may not be assigned or otherwise transferred (in whole or in part, whether voluntarily, by operation of law or otherwise) by either
Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided, however, that such consent shall not be required for assignment or transfer of this Agreement in connection with an assignment
or transfer of the License Agreement as permitted under Section 12.2 thereof. Notwithstanding the foregoing, any such assignment or transfer to an Affiliate shall not relieve the assigning Party of its responsibilities for performance of its
obligations under this Agreement. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. Any attempted assignment not in accordance with
this Agreement shall be void. 
 5.3 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all
such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 5.4 Notices. All notices under
this Agreement by one Party to the other Party shall be given in accordance with Section 12.4 of the License Agreement. 
 5.5 Amendment. No
amendment, modification or supplement of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized representative of each Party. 
 5.6 Waiver. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed
by a duly authorized officer of the waiving Party. 
 5.7 Counterparts; Facsimile Signatures. This Agreement may be executed in counterparts and such
counterparts taken together shall constitute one and the same agreement. This Agreement may be executed by facsimile signatures, which signatures shall have the same force and effect as original signatures. 
  

 5 

 5.8 Descriptive Headings. The descriptive headings of this Agreement are for convenience only, and shall be of no
force or effect in construing or interpreting any of the provisions of this Agreement. 
 5.9 Governing Law; Dispute Resolution. This Agreement shall
be governed and construed in accordance with the laws of the State of New York, without giving effect to any choice of law provisions thereof. Prior to bringing any legal action against the other Party, the Parties shall comply with the dispute
resolution procedures required under Section 12.9 of the License Agreement with respect to such dispute. 
 5.10 Severability. If any provision
hereof should be held invalid, illegal or unenforceable in any respect in any jurisdiction, the Parties hereto shall use reasonable efforts to substitute, by mutual written consent, valid provisions for such invalid, illegal or unenforceable
provisions which valid provisions in their economic effect are sufficiently similar to the invalid, illegal or unenforceable provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid
provisions. In case such valid provisions cannot be agreed upon, the invalid, illegal or unenforceable provisions of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provisions
are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provisions. 
 5.11 Entire Agreement of the Parties. This Agreement hereby, together with the License Agreement and the Schedules and Exhibits hereto and thereto, constitutes
and contains the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements whether oral or written, between the Parties
respecting the subject matter hereof. 
 5.12 Independent Parties. The relationship between the Parties created by this Agreement is one of
independent contractors and is not a joint venture, partnership or any similar arrangement. Neither Party shall have the power or authority to bind or obligate the other except as expressly set forth in this Agreement. 
 5.13 Accrued Rights; Surviving Obligations. Unless explicitly provided otherwise in this Agreement, termination, relinquishment or expiration of this Agreement
for any reason shall be without prejudice to any rights that shall have accrued to the benefit to any Party prior to such termination, relinquishment or expiration, including damages arising from any breach hereunder. Such termination,
relinquishment or expiration shall not relieve any Party from obligations which are expressly indicated to survive termination or expiration of the Agreement, including, without limitation, those obligations set forth in Sections 4.4 and 4.5 and
Article 1 (to the extent required to enforce other surviving rights and/or obligations) and Article 5 hereof. 
 5.14 Injunctive Relief. Inspire
acknowledges and agrees that InSite would be irreparably damaged if any of the provisions of this Agreement are not performed by Inspire in accordance with their specific terms, and that any breach of, threatened breach of, or failure to perform or
comply with, this Agreement by Inspire could not be adequately compensated in all cases by monetary damages alone. Accordingly, in addition to any other right or remedy to which InSite 

  

 6 

 
may be entitled at law or in equity, InSite shall be entitled to temporary, preliminary and permanent injunctive relief to prevent breaches or threatened
breaches of any of the provisions of this Agreement, without posting any bond or other undertaking. 
 5.15 Expenses. Unless otherwise provided
herein, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the Party that shall have incurred the same and the other Party shall have no liability relating thereto. 

5.16 No Third Party Beneficiaries. No person or entity other than the Parties hereto and their respective Affiliates, successors and permitted assigns shall be
deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement. 
 5.17 No Strict Construction. This Agreement
has been prepared jointly and shall not be strictly construed against either Party. 
 [Signature Page Immediately Follows] 

 

 7 

 IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed this Agreement as of the Effective
Date. 
  

			
	INSITE VISION INCORPORATED
		
	By:	 	 /s/ S. Kumar Chandrasekaran

	Name:	 	S. Kumar Chandrasekaran
	Title:	 	CEO
	
	INSPIRE PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Christy L. Shaffer

	Name:	 	Christy L. Shaffer
	Title:	 	President & CEO

 SIGNATURE PAGE TO TRADEMARK LICENSE AGREEMENT 
  

 8 

 Schedule 1 
 InSite Trademarks 
 Trademarks 
 U.S.: 
 DuraSite 
 DuraSite®
US Trademark Number: 1769077 
 AzaSite 
 AzaSiteTM US Trademark Application Number: 78/426,374 
 Canada:

 DuraSite 
 DuraSite® Canadian Registration Number 432299 
 AzaSite 
 AzaSiteTM Canadian Trademark Application Number 1325128

 Domain Name 
 www.AzaSite.com

  

 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]